Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Antonuzzo

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
The Oncologist|May 14, 2025
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecanAnna Amela Valsecchi, Simona Pisegna, Andrea Antonuzzo, et al.
European Thyroid Journal|May 27, 2022
Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockadeAlessandro Brancatella, Laura Pierotti, Nicola Viola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patientsCarmelo Tibaldi, Elisa Giovannetti, Enrico Vasile, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2009
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancerAndrea Fontana, Luca Galli, Anna Fioravanti, et al.
Vaccines|June 24, 2022
Safety and Tolerability of COVID-19 Vaccines in Patients with Cancer: A Single Center Retrospective AnalysisAmedeo Nuzzo, Simona Manacorda, Enrico Sammarco, et al.
Neuroendocrinology|January 21, 2016
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological FactorsFrancesca Spada, Lorenzo Antonuzzo, Riccardo Marconcini, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 8, 2018
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO)Fausto Roila, Guglielmo Fumi, Benedetta Ruggeri, et al.
Clinical Genitourinary Cancer|January 1, 2020
On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective StudyElena Bolzacchini, Graziella Pinotti, Lorenza Bertù, et al.
Journal of Neuro-Oncology|February 18, 2014
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesPaola Queirolo, Francesco Spagnolo, Paolo Antonio Ascierto, et al.
The Oncologist|March 18, 2020
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune DisordersAndrea Antonuzzo, Fabio Calabrò, Pietro Quaglino, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
The Oncologist|May 14, 2025
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecanAnna Amela Valsecchi, Simona Pisegna, Andrea Antonuzzo, et al.
European Thyroid Journal|May 27, 2022
Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockadeAlessandro Brancatella, Laura Pierotti, Nicola Viola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patientsCarmelo Tibaldi, Elisa Giovannetti, Enrico Vasile, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2009
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancerAndrea Fontana, Luca Galli, Anna Fioravanti, et al.
Vaccines|June 24, 2022
Safety and Tolerability of COVID-19 Vaccines in Patients with Cancer: A Single Center Retrospective AnalysisAmedeo Nuzzo, Simona Manacorda, Enrico Sammarco, et al.
Neuroendocrinology|January 21, 2016
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological FactorsFrancesca Spada, Lorenzo Antonuzzo, Riccardo Marconcini, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 8, 2018
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO)Fausto Roila, Guglielmo Fumi, Benedetta Ruggeri, et al.
Clinical Genitourinary Cancer|January 1, 2020
On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective StudyElena Bolzacchini, Graziella Pinotti, Lorenza Bertù, et al.
Journal of Neuro-Oncology|February 18, 2014
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesPaola Queirolo, Francesco Spagnolo, Paolo Antonio Ascierto, et al.
The Oncologist|March 18, 2020
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune DisordersAndrea Antonuzzo, Fabio Calabrò, Pietro Quaglino, et al.
Pageof 6